During the corresponding time, Anika Therapeutics Inc recorded a revenue increase by 19.18 % year on year, sequentially revenue grew by 12.46 %. While revenue at the Anika Therapeutics Inc 's corporate clients
Anika Therapeutics Inc's Comment on Sales, Marketing and Customers
The company is preparing for potential U.S. approval and launch of Hyalofast and Cingal, each representing an incremental U.S. addressable market of at least $1 billion. It has submitted a premarket approval application for Hyalofast to the FDA and is engaging with the FDA regarding Cingal's regulatory approval. The company is building on the international commercial momentum of its osteoarthritis pain management portfolio, led by Monovisc and Cingal. The company sold Arthrosurface Incorporated to Phoenix Brio, Incorporated, receiving a promissory note and potential revenue payments based on net sales of certain products. It also sold Parcus Medical, LLC to Medacta Americas Manufacturing, Inc., receiving $4.5 million in cash at closing.
Anika Therapeutics Inc’s Comment on Sales, Marketing and Customers
The company is preparing for potential U.S. approval and launch of Hyalofast and Cingal, each representing an incremental U.S. addressable market of at least $1 billion. It has submitted a premarket approval application for Hyalofast to the FDA and is engaging with the FDA regarding Cingal's regulatory approval. The company is building on the international commercial momentum of its osteoarthritis pain management portfolio, led by Monovisc and Cingal. The company sold Arthrosurface Incorporated to Phoenix Brio, Incorporated, receiving a promissory note and potential revenue payments based on net sales of certain products. It also sold Parcus Medical, LLC to Medacta Americas Manufacturing, Inc., receiving $4.5 million in cash at closing.
Sources:
Anika Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Anika Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Anika Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
109.6 %